Research Article

Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population

Table 5

Allelic odds ratios and 95% confidence intervals for comparison of TNFRSF1B variants with IBD status in New Zealand IBD patients and Caucasians.

Allelic odds ratios and 95%Allelic odds ratios and 95%Allelic odds ratios and 95%
confidence intervals for comparison ofconfidence intervals for comparison of confidence intervals for comparison of
TNFRSF1_B1061622TNFRSF1B_1061624TNFRSF1B_3397
Crohns diseaseUlcerative colitisCrohns diseaseUlcerative colitisCrohns diseaseUlcerative colitis
OR95% CIOR95% CIOR95% CIOR95% CIOR95% CIOR95% CI

Female1.20 1.38 1.10 1.00 0.85 0.96
Male1.05 1.02 0.82 0.79 0.89 1.04
Age at first diagnosis
0–16 years0.85 1.08 0.88 1.30 0.86 1.22
17–40 years1.26 1.18 1.01 0.93 0.85 0.96
40 years1.01 1.24 0.95 0.83 0.89 1.00
CD location
Ileal0.91 1.13 0.88
Colonic1.17 0.90 0.91
Ileocolonic1.27 0.90 0.78
UC location
Pancolitis1.13 0.94 1.14
Left colon1.24 0.73 0.92
Proctitis1.27 1.00 0.93
CD Behavior
Inflammatory1.17 0.88 0.92
Stricturing1.03 1.01 0.90
Penetrating1.13 1.38 0.62
Ileal/stricturing0.86 1.03 0.93
Colonic/inflammatory1.24 0.84 0.93
Any relative with IBD1.22 1.15 0.78 0.88 0.97 0.83
Bowel resection0.93 1.10 1.09 0.79 0.77 1.29
Smoker at diagnosis0.96 1.16 1.01 0.62 0.92 1.22
Ever used immunomodulators1.08 1.43 1.07 1.16 0.82 0.88
Any EIMs1.05 1.05 1.06 0.83 0.89 0.81